Chemoinformaics analysis of Norxanthantolides
| Molecular Weight | 194.23 | nRot | 0 |
| Heavy Atom Molecular Weight | 180.118 | nRig | 12 |
| Exact Molecular Weight | 194.094 | nRing | 2 |
| Solubility: LogS | -1.649 | nHRing | 1 |
| Solubility: LogP | 1.575 | No. of Aliphatic Rings | 2 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 1 |
| Atoms Count | 28 | No. of Aliphatic Hetero Cycles | 1 |
| No. of Heavy Atom | 14 | No. of Aromatic Carbocycles | 0 |
| nHetero | 3 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 14 | No. of Saturated Hetero Cycles | 1 |
| No. of Carbon atom | 11 | No. of Saturated Rings | 1 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 3 | No. of Arom Bond | 0 |
| nHA | 3 | APOL | 30.1111 |
| nHD | 0 | BPOL | 17.5169 |
| QED | 0.642 |
| Synth | 3.841 |
| Natural Product Likeliness | 1.062 |
| NR-PPAR-gamma | 0.138 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0.001 |
| Pgp-sub | 0.008 |
| HIA | 0.006 |
| CACO-2 | -4.631 |
| MDCK | 0.0000239 |
| BBB | 0.307 |
| PPB | 0.942722 |
| VDSS | 0.632 |
| FU | 0.0770942 |
| CYP1A2-inh | 0.122 |
| CYP1A2-sub | 0.8 |
| CYP2c19-inh | 0.022 |
| CYP2c19-sub | 0.55 |
| CYP2c9-inh | 0.034 |
| CYP2c9-sub | 0.861 |
| CYP2d6-inh | 0.005 |
| CYP2d6-sub | 0.854 |
| CYP3a4-inh | 0.011 |
| CYP3a4-sub | 0.206 |
| CL | 15.836 |
| T12 | 0.895 |
| hERG | 0.003 |
| Ames | 0.017 |
| ROA | 0.155 |
| SkinSen | 0.285 |
| Carcinogencity | 0.827 |
| EI | 0.032 |
| Respiratory | 0.25 |
| NR-Aromatase | 0.617 |
| Antiviral | No |
| Prediction | 0.707684 |